Strategies to Maximize the Clinical Benefit of EGFR TKIs in Advanced NSCLC (May 2019) is organized by Clinical Care Options (CCO), LLC and will be held on May 31, 2019 at Sheraton Grand Chicago, Chicago, Illinois, United States of America.
This program is intended for physicians, oncology nurses, pharmacists, and other healthcare providers who care for patients with non-small-cell lung cancer.
Physician Continuing Medical Education:
The Postgraduate Institute for Medicine designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Education:
The maximum number of hours awarded for this Continuing Nursing Education activity is 2.0 contact hours.
Pharmacist Continuing Education:
Postgraduate Institute for Medicine designates this continuing education activity for 2.0 contact hours (0.2 CEUs) of the Accreditation Council for Pharmacy Education.
The goal of this activity is to improve participants’ knowledge of and competence in applying EGFR inhibitors in the treatment of patients with EGFR-mutated non-small-cell lung cancer.
• Apply expert recommendations for frontline therapy for advanced EGFR-mutated NSCLC focusing on safety, efficacy, and the individualization of therapy based on tumor-specific and patient-specific factors
• Compare the efficacy and safety of first-generation EGFR TKIs with later-generation EGFR TKIs
• Examine current recommendations for molecular testing and the roles for liquid biopsies in guiding the use of EGFR TKI therapy
• Plan optimal sequencing of EGFR TKIs after considering the available evidence and expert recommendations
• Evaluate current and evolving treatment approaches to address acquired resistance and progression in advanced EGFR-mutated NSCLC
|Contact No. :||1-855-224-2241
Conference Fee Details
|Early Fee Last date||:||NA|